ALZ-801
Alzheon
[]
join alzheon, cso, john hey, phd today at #aanam for a podium presentation: effects of alz-801, an oral amyloid oligomer inhibitor, on biomarkers of alzheimer s disease (ad): 12-month results of phase 2 biomarker study in early ad 2:12 pm, s26. #alzheimers #aan2023 
Alzheon is at the forefront of delivering the first oral treatment to patients suffering from Alzheimer's Disease. Retweets are not endorsements.